Literature DB >> 22037048

Synthesis of deguelin-biotin conjugates and investigation into deguelin's interactions.

José Garcia1, Sofia Barluenga, Katarzyna Gorska, Florenz Sasse, Nicolas Winssinger.   

Abstract

Deguelin, a rotenoid, has emerged as an attractive pharmacophore for chemoprevention showing in vivo activity in several xenografts. Recently, several lines of evidence have suggested its mode of action may involve inhibition of HSP90, however binding in a different mode than known pharmacophores. To further probe the target of deguelin and related rotenoids, several biotin conjugates were prepared. None of the conjugates showed significant affinity for HSP90, however two conjugates showed a strong cellular co-localization with mitochondria, consistent with binding to mitochondrial complex 1. Contrarily to rotenone, deguelin and tephrosin were not found to inhibit tubulin polymerization demonstrating a dramatic pharmacological difference between these closely related rotenoids.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037048     DOI: 10.1016/j.bmc.2011.09.064

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Allylic azides: synthesis, reactivity, and the Winstein rearrangement.

Authors:  Angela S Carlson; Joseph J Topczewski
Journal:  Org Biomol Chem       Date:  2019-05-08       Impact factor: 3.876

2.  A Concise Enantioselective Synthesis and Cytotoxic Evaluation of the Anticancer Rotenoid Deguelin Enabled by a Tandem Knoevenagel/Conjugate Addition/Decarboxylation Sequence.

Authors:  Rebecca L Farmer; Karl A Scheidt
Journal:  Chem Sci       Date:  2013-08       Impact factor: 9.825

3.  Hydroxylated Rotenoids Selectively Inhibit the Proliferation of Prostate Cancer Cells.

Authors:  David A Russell; Hannah R Bridges; Riccardo Serreli; Sarah L Kidd; Natalia Mateu; Thomas J Osberger; Hannah F Sore; Judy Hirst; David R Spring
Journal:  J Nat Prod       Date:  2020-05-27       Impact factor: 4.050

4.  Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells.

Authors:  Adam Naguib; Grinu Mathew; Colleen R Reczek; Kaitlin Watrud; Alexandra Ambrico; Tali Herzka; Irene Casanova Salas; Matthew F Lee; Nour El-Amine; Wu Zheng; M Emilia Di Francesco; Joseph R Marszalek; Darryl J Pappin; Navdeep S Chandel; Lloyd C Trotman
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.995

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.